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The anti-Trypanosoma cruzi activity of natural products isolated from Azorella compacta was evaluated, with
particular emphasis on their effect against intracellular amastigotes. Five diterpenoids from A. compacta derived from
mulinane and azorellane were isolated and identified. Only two products, named azorellanol (Y-2) and mulin-11,3-
dien-20-oic acid (Y-5), showed trypanocidal activity against all stages of  T. cruzi including intracellular amastigotes.
At 10 µM, these compounds displayed a strong lytic activity. It ranged from 88.4 ± 0.6 to 99.0 ± 1 %  for all strains and
stages evaluate, with an IC50 /18 h   values of 20-84 µM and 41-87 µM, respectively. The development of intracellular
amastigotes was also inhibited by nearly 60% at 25 µM. The trypanocidal molecules Y-2 and Y-5 did show different
degrees of cytotoxicity depending on the cell line tested, with an IC50 /24 h ranging from 33.2 to 161.2 µM.
 We evaluated the effect of diterpenoids against intracellular T. cruzi forms by immunofluorescent identification
of a specific membrane molecular marker (Ssp-4 antigen) of the T. cruzi amastigote forms. The accuracy and repro-
ducibility of the measurements were found to be outstanding when examined by confocal microscopy.
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Chagas disease caused by Trypanosoma cruzi is a
major public health problem in South America where nearly
20 million people  are infected by T. cruzi and 90 million
are at risk in endemic areas (WHO 2000).
There is no satisfactory chemotherapy for the disease
in any of its phases. The two main drugs used in clinical
practice, nifurtimox and benznidazole, produce strong side
effects and do not eliminate the parasite during short-
term therapies or during the chronic and inapparent phases
of the disease (Urbina 1999, Coura & de Castro 2002).
Similarly, there are no adequate chemoprophylactic drugs
to be used to eliminate the parasite from the blood of
serologically positive donors. The prevention of transfu-
sion-associated Chagas disease has been attempted
through clinical and serologic screening of blood donors
and/or by the addition of trypanomicidal substances such
as gentian violet to store blood for 24 h. However the
compounds confers a blue color to the recipients and its
use has been restricted in endemic areas. This dye kills
trypomastigotes in vitro at 4°C. When used  in concentra-
tions of 125 mg/500 ml, and the blood is stored for 24 h
before use, transmission is avoided. This strategy has
been used extensively in some countries, like Brazil, with-
out  apparent side effects, except that patients may be-
come stained for short periods of time (Schmunis 1999).
Due to the high costs involved in the development
and registration of new drugs, the pharmaceutical indus-
try has withdrawn funds for research and development of
new compounds for the treatment of tropical diseases.
Therefore, there is an urgent need to support novel re-
search on natural products with anti-T. cruzi activity
(WHO 2000).
The high altitude and desert-like environment of the
Andean Mountains in Northern Chile allow the growth of
a native macroflora under extreme conditions. Two plants,
yareta (Azorella compacta) and chuquican (Mulinum
crassifolium), from the Umbelliferae family are rich sources
of diterpenoids, compounds with a variety of  biological
activities (Esquivel et al. 1989, Loyola et al. 1996, 1997a).
Both plants are extensively used in folk medicine against
diabetes, bronchitis, high-altitude sickness, pneumonia,
rheumatism, and have also wound healing effects (Gunckel
1967,  Wickens 1995).
In previous studies (Neira et al. 1998), diterpenoids
from A. compacta showed activity against extracellular
amastigotes from highly infected Vero cells. These results
do not show what would be the real activity of these com-
pounds against amastigotes since these are intracellular
forms of the parasite; therefore, drugs should enter the
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host cell and maintain inside their amastigocidal activity.
In the present study, we address this problem by evaluat-
ing the anti-T. cruzi activity of five diterpenoids isolated
from A. compacta, against the intracellular amastigote
forms, introducing confocal microscopy as an analysis
tool.
MATERIALS AND METHODS
Extraction and isolation of natural products from A.
compacta - Plants were collected in the El Tatio area, 4,000
m above sea level. A voucher specimen was deposited
at the herbarium of Universidad de Concepción,
Concepción, Chile, and identified by Prof. C Marticorena.
The dried and finely powdered whole plant was extracted
at room temperature with petroleum ether (PE), followed
by extraction with dichloromethane and finally with
ethanol:water (1:1). The solvent was eliminated using a
rotary evaporator at approximately 40ºC, and different ex-
tracts were obtained. The extracts were submitted to chro-
matography on silica gel, alumina or Sephadex LH-20 col-
umns and eluted with a solvent mixture of increasing po-
larity (0-100% EtOAc-PE, or CH2Cl2-MeOH). Compound
separation was monitored by thin-layer chromatography.
The compounds were isolated and purified through col-
umn and thin-layer chromatographies, and the derivatives
were submitted to  crystallization, sublimation and vacuum
distillation, as previously described (Loyola et al. 1996).
The structure of the natural products was determined by
spectroscopic techniques in homo- and heteronuclear 2D-
NMR experiments (Loyola et al. 1996).
Natural products - All pure compounds from A. com-
pacta were dissolved in water with  1%  dimethyl sulfox-
ide (DMSO) at a final concentration of 10 mM. DMSO was
filtered in Millepore (0.2 µm)  membrane and aseptically
added to the tubes.
Cell cultures - Vero cells, HeLa cells, and J-774 murine
macrophages were maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum at 37ºC, in 75
cm3 growth flasks, using a cell culture incubator under a
5% CO2 humid atmosphere.
Parasites - Epimastigote, trypomastigote and
amastigote forms of the Tulahuen  and SPA-14 (González
et al. 1995) strains of T. cruzi, were used in this study. We
also used the CL Brener clone from the CL strain isolated
by Brener and Chiari (1963). Parasites were maintained in
Swiss mice and axenic growth medium. Epimastigotes
were obtained from LIT medium (Camargo 1964) and
trypomastigotes  from cell cultures (de Diego et al. 1988).
Intracellular amastigotes were obtained by infecting Vero
cells and/or HeLa cells with cultured trypomastigotes by
the method of González (1991). Extracellular amastigotes
were obtained as previously described (Tomlinson et al.
1995).
Determination of the trypanocidal activity of the natu-
ral products against different stages of  T. cruzi - Experi-
ments were carried out according to González et al. (1990).
Firstly, 45 µl of each compound were added to the first
well of a 96-well microtiter plate and two-fold dilutions
were performed to reach a final concentration range of 1
to 125 µM. Next, each well received 45 µl of a suspension
containing 4x106 epimastigotes and plates were incubated
for 18 h at 28ºC. A viability control (1% DMSO) and a
mortality control (1 mM crystal violet) were included. No
effect  on drug toxicity attributable to DMSO was ob-
served at the maximum concentration used of 1%. The
trypanocidal activity was measured as percent of mortal-
ity after microscopic observation of 50 fields. A viability
test was performed using an exclusion dye as described
(Jacque et al. 1975). Trypanocidal IC50/18 h against
trypomastigotes and extracellular amastigotes was deter-
mined as described for epimastigotes, but plates were in-
cubated at 37°C.
Trypanocidal activity against intracellular am-
astigotes - Five-hundred µl of a suspension containing 7
x 104 Vero cells/ml were seeded on  24-well microplates
incubated for 18 h under a 5% CO2 atmosphere in order to
obtain cell adherence. Next, the cells were washed and
infected with  trypomastigotes of the clone CL Brener at a
ratio of 10 parasites per cell, for 3 h. The cells were washed
with RPMI to remove extracellular parasites. Finally, the
infected culture was treated with each compounds (25
µM) for 24 h. Inhibition of intracellular growth was deter-
mined by counting the number of intracellular amastigotes
in 100 infected cells. In order to compare the results, two
parallel procedures were employed: (a) light microscopy
of cells stained using the classical May Grünwald-Giemsa
method;  (b) confocal immunofluorescence microscopy
using Mab 1D9, an anti-Ssp-4 monoclonal antibody
(Barros et al. 1997).
Cytotoxic activity against mammalians cells - Five-
hundred µl of a suspension containing 7 x 104/ml of Vero
cells, HeLa cells or J774 macrophages were added to 24-
well microplates and the cells were left to adhere and grow
for 24 h. Cells were washed with RPMI and incubated
with different concentrations of each compound for 24 h.
Cytotoxicity was evaluated using exclusion dyes, as indi-
cated previously.
All assays were carried out in triplicate using nifurtimox
(35-173 µM)   and crystal violet (1 µM) as controls. IC50
values were determined by probit analysis by the method
of Finney (1971).
RESULTS
Five diterpenoids derived from mulinane and azorellane
were isolated from A. compacta extracts (Fig. 1). The chemi-
cal structure was elucidated by spectroscopic and chemi-
cal methods. The molecules Y-1, Y-4 and Y-5 were chemi-
cally identical to mulinolic acid, mulinic acid and mulin-
11,3-dien-20-oic acid, respectively. Their carbon skeleton
corresponded to mulinane and they have been previously
isolated from Mulinum crassifolium (Loyola et al. 1996,
1997a). Two other  molecules were detected for the first
time and were denominated azorellanol (Y-2) and
desacetylazorellanol (Y-3) because they have a cyclopro-
pane ring between carbons C-9 and C-12 of the mulinane
skeleton. This new carbon skeleton was named azorellane
(Loyola et al. 1997b).
The in vitro trypanocidal activity of these diterpenoids
against different stages of the Tulahuen and SPA-14 strains
and the CL Brener clone of T. cruzi is shown in Table I. At
10 µM, after 18 h incubation, only two molecules,  the
azorellanol (Y-2) and mulin-11,13-dien-20-oic acid (Y-5),
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shown).  At 1 mM,  gentian violet used as control shown
a 100% lysis.
Table II shows the cytotoxic activity of the various
compounds against  different mammalians cells. Com-
pounds Y-1, Y-3 and Y-4  showed no cytotoxic activity.
The trypanocidal molecules Y-2 and Y-5 showed different
degrees of cytotoxicity depending on the cell line tested,
with IC50 ranging between 33.2 and 161.2 µM  after 24 h
incubation.
At 25 µM, compounds Y-2 and Y-5 showed trypano-
cidal activity against intracellular amastigotes of clone
CL Brener, inhibiting the growth of the protozoan by nearly
60% (Table III). After 24 h incubation at 37°C, the IC50 for
diterpenoids Y-2 and Y-5 was 71.7 µM and 49.7 µM, re-
spectively by May-Grünwald-Giemsa staining, and 32.3
µM and 29 µM, respectively, by immunofluorescence con-
focal microscopy (date not shown). These differences
could be explained by the fact that Giemsa staining do not
measures cell vitality and do not provide information about
cell integrity. On the other hand, immunofluorescence al-
lows detection of viable intracellular amastigotes, since
they are  synthetizing and expressing a particular antigen
and also have an intact cytoplasmic membrane as indi-
cated by the reactivity of monoclonal antibody against
the Ssp-4 epitope.
Accuracy and reproducibility in detection of  viable
intracellular amastigotes were greatly improved by the use
of confocal fluorescence microscopy. Fig. 2 shows the
results of the intracellular amastigote clone CL Brener
photographed by confocal microscopy after treatment with
Y-2, Y-3 and Y-5 diterpenoids (2, 3 and 4). There was a
clear decrease in Ssp-4 labeling in amastigotes treated
with 25 µM Y-2 or Y-5 when compared with controls (1).
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Fig. 1: structure of diterpenoids isolated from Azorella compacta;
the molecules Y-1, Y-4 and Y-5 are mulinolic acid, mulinic acid and
mulin-11,3-dien-20-oic acid, respectively. Y-2 and Y-3 were iden-
tified for the first time and were denominated azorellanol and
desacetylazorellanol because they have a cyclopropane ring be-
tween carbons C-9 and C-12 of the mulinane skeleton.
 TABLE I
Lysis of epimastigotes (E), trypomastigotes (T) and axenic amastigotes (A) from different Trypanosoma cruzi strains by
diterpenoids from Azorella compacta
Population (%  lysis)
Diterpenoid Tulahuen SPA–14 CL Brener
(10 µM)  E T A E T A E T A
Y-1 2.5  ± 0.2  3.9 ± 0.4   3.5 ± 0.4 2.7 ± 0.2  3.5 ± 0.2  3.3 ± 0.3  1.6 ± 0.2  2.4 ± 0.2 2.2 ± 0.4
Y-2   89 ± 0.8 97.5 ± 0.5  95.2 ± 1.0  98 ± 0.6 97.4 ± 0.8 88.4 ± 0.8 97.3 ± 0.8   99 ± 1.0 96 ± 0.8
Y-3     2 ± 0.3  2.8 ± 0.4    2.4 ± 0.4 3.2 ± 0.4  3.4 ± 0.4  3.1 ± 0.2   2.1 ± 0.1  2.6 ± 0.3 2.2 ± 0.2
Y-4   2.2 ± 0.2  3.1 ± 0.3     2.9 ± 0.3 2.5 ± 0.2     3 ± 0.4  2.9 ± 0.3   2.6 ± 0.4  2.8 ± 0.2 2.7 ± 0.3
Y-5    96 ± 1.0 98.4 ± 0.6   97.1 ± 1.0  93 ± 0.8 97.8 ± 0.9   95 ± 0.5 96.7 ± 0.9 97.2 ± 0.4 92 ± 0.6
TABLE II
Cytotoxic effect (IC50) of Azorella compacta diterpenoids on Vero, HeLa, and J-774 macrophages cell lines
IC50 (µM)/24 h
Diterpenoids
Cells Y-1 Y-2 Y-3 Y-4 Y-5 Nifurtimox Crystal violet
Vero > 1000 161.2 > 1000 > 1000 129.3 106.4  97.0
HeLa > 1000 121.2 > 1000 > 1000 143.4 103.1   21.2
J-774 > 1000 37.4 > 1000 > 1000   33.2 145.5   33.3
showed a strong trypanocidal activity with a percentage
of cell lysis ranging between 88.4 ± 0.6 and 99 ± 1 for all
the strains and stages studied. The IC50 ranged from 20
to 84 µM for Y-2 and from 41 to 87 µM for Y-5 in assays
against the different developing forms studied (data not
416 Trypanocidal Activity of A. compacta • Jorge E Araya et al.
DISCUSSION
In many regions of the world plants have been used in
traditional medicine. This fact strongly suggests that they
contain products with pharmacological activity. Among
parasitic diseases, the examples of quinine and artemisin
reinforce the idea that plants could be important sources
of new pharmaceuticals.
In Chagas disease, most of the attempts to develop an
efficient and safe chemotherapy has been unsuccessful.
Currently available drugs (nitrofurans and nitroimida-
zoles), developed empirically over three decades ago, are
unsatisfactory due to frequent toxic side effects and lim-
ited efficacy, particularly in the prevalent chronic form of
the disease. Furthermore, studies of their mechanism of
action have shown that their antiparasitic activity is inex-
tricably linked to mammalian host toxicity (Urbina 2002).
The efficacy of these drugs also depends on the suscep-
tibility of T. cruzi strains. The drugs are also genotoxic
and produce biochemical damage to mammalian tissues.
On the other hand,  although  T. cruzi, requires specific
endogenous sterols for cell viability and proliferation, the
currently available antifungal sterol biosynthesis inhibi-
tors are not powerful enough to induce parasitological
cures of human or experimental infections. However, new
triazole antifungal compounds, which are potent inhibi-
tors of the sterol C14 alpha demethylase of the parasite
and have special pharmacokinetic properties, are capable
of inducing parasitological cures in murine models of both
acute and chronic Chagas disease. They are currently the
most advanced candidates for clinical trials in patients
with Chagas disease (Molina et al. 2000, Urbina  2001).
Allopurinol and related compounds also reduce the para-
sitemia and induce a negative xenodiagnosis, but these
effects may not be permanent, a fact that invalidates their
clinical use (Stoppani 1999).
Among the various tests used to evaluate cytotoxic-
ity and the viability of cell cultures exposed to drugs or
active compounds, cell line systems such as the one used
in the present study are the most sensitive and best re-
produce the conditions that may  occur in mammals.
In vitro cytotoxicity tests against mammalian cells
should be followed by more precise methods, such as
cytogenetic activity. Nifurtimox has been shown to be at
least four-fold more toxic than benznidazole in a mutagen-
esis test against Salmonella strain TA100, at a concen-
tration of 35 µg per plaque (Ferreira & Ferreira 1986).
Differents publications have described the trypano-
cidal effect of natural products and extracts from species
of Senecio (Sarti el al. 1984), some naphthoquinones (Pinto
et al. 1987), gossypol (Rovai et al. 1990), boldine (Morello
et al. 1994), 1,4 naphthoquinones (Morello et al. 1995) and
β-carboline alkaloids (Rivas et al. 1999). In addition,
Brengio et al. (2000) have reported that the sesquiterpene
lactone dehydroleucodine inhibited the growth of cultured
T. cruzi epimastigotes .
Our work shows that azorellanol (Y-2) and mulin-11,3-
dien-20-oic acid (Y-5) have trypanocidal effects against
all developing stages of T. cruzi. These appears to be an
interesting attribute of these class of compounds, if we
consider that several other diterpenoids isolated from
plants have shown anti-T. cruzi activities. In fact, earlier
studies  of Alves et al. (1995)  showed  that diterpene ent-
kaur-16-en-19-oic acid, isolated from Mikania obtusata
displayed trypanocidal activity against trypomastigotes
of T. cruzi. On the other hand, we have previously re-
ported  the trypanocidal activity of two diterpenoids
(Azorellanol and mulin-11,13 -dien-20-oico acid) against
extracellular amastigotes of  the CL Brener clone, SPA-14
and G  T. cruzi strains transformed in axenic culture at pH
5.0, using  the microscopic observation to detect the ef-
fect of compounds on amastigote forms (Neira et al. 1998).
Giemsa staining of infected cells has been used for a
long time as a routine laboratory procedure for counting
intracellular amastigotes. However, this method has been
reported to be of  low  accuracy and with high time con-
suming (Martinez et al. 2000). This approach is based
mainly on the morphological  stained parasite identifica-
tion.
Thus, we propose the use of a complementary method
to evaluate the activity of biomolecules against intracel-
lular forms of T. cruzi using immunofluorescence to de-
tect a cell membrane marker, the Ssp4 antigen specific for
T. cruzi amastigotes (Andrews et al. 1987, Burleigh &
Andrews 1995). This antigen can be identified with a
monoclonal antibody (1D9) that recognizes an Ssp-4 sur-
face glycoprotein which is expressed in all potentially vi-
able intracellular forms of the parasite (Barros et al. 1997).
Confocal scanning fluorescence microscopy has be-
come widely used in cell biology and pathology. Mono-
clonal antibodies are a powerful  tool that enables de-
tailed studies of tissue forms of T. cruzi (Mortara et al.
1999, 2000). Confocal microscope systems can store and
process digitalized images that can be readily accessible.
Although expensive, this procedure has the significant
advantage of being a highly sensitive, specific and repro-
ducible method that would improve the evaluation of the
activity of different compounds against the intracellular
stages of the parasite.
Finally, we may conclude that two diterpenoid com-
pounds isolated from A. compacta showed trypanocidal
activity as demonstrated by conventional procedures as
well as by immunofluorescence confocal microscopy. The
next step will be to determine the pharmacokinetic and
pharmacodynamic properties of these natural products.
TABLE III
Trypanocidal effect of Azorella compacta diterpenoids on
intracellular amastigotes of the Trypanosoma cruzi clone CL
Brener determined by light and confocal immunofluorescence
microscopy
 Number of amastigotes/100 cells
Diterpenoids Light microscopy Confocal microscopy
(25 µM) (May Grunwald-Giemsa) (Immunofluorescence)
Y-1 101.5 ± 3.5 125.6 ± 4.4
Y-2  42.3 ± 0.6  57.7 ± 0.9
Y-3 104.5 ± 3.6 132.3 ± 4.9
Y-4 111.1 ± 2.5 135.4 ± 3.3
 Y-5   39.6 ± 0.8   52.5 ± 1.0
Nifurtimox a   37.8 ± 2.4   41.6 ± 3.0
a: control final concentration of  nifurtimox = 35 µM
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Fig. 2: photomicrographs of intracellular amastigote clone CL Brener after treatment with Y-2, Y-3 and Y-5 diterpenoids (2, 3 and 4).
There was a clear decrease in Ssp-4 labeling in amastigotes treated with 25 µM Y-2 or Y-5 when compared with control (1).
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